Reporte zur Charge FJ-1614-PFIZER-

Symptomtext

COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non-HCP) from product quality. The reporter is the patient. A 39-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 30Mar2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 20Apr2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 07Jan2022 as dose 3 (booster), single (Lot number: FJ-1614-PFIZER-2021), in left arm for covid-19 immunisation. The patient's relevant medical history included: "OCD" (unspecified if ongoing); "GAD" (unspecified if ongoing); "GERD" (unspecified if ongoing). Concomitant medication(s) included: WELLBUTRIN; LAMICTAL; BUSPAR; CLARITIN ALLERGIC; GABAPENTIN; IBUPROFEN. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (10Jun2022) Positive, notes: Positive COVID PCR test posttreatment with Paxlovid. Therapeutic measures were taken as a result of vaccination failure, covid-19 with Paxlovid. Additional information: The patient had no known allergies. Patient received treatment for COVID-19. Anti-viral details: Product=COVID 19 Treatment. Brand- Paxlovid. Treatment start date- 04Jun2022. Treatment stop date- 08Jun2022. Indication- Treatment of COVID-19. Other medication in last 2 weeks details: Wellbutrin, Lamictal, Buspar, Claritin, Gabapentin Ibuprofen. Adverse event: Positive COVID PCR test post treatment with Paxlovid. Return of sore throat, chest soreness, fatigue, nasal congestion. The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.